2-[(ethoxy)carbonyl]-5-[(4-fluorophenyl)methyl]-3-pyridinecarboxylic acid | 863442-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-[(ethoxy)carbonyl]-5-[(4-fluorophenyl)methyl]-3-pyridinecarboxylic acid
• 英文别名: 5-(4-fluorobenzyl)-2,3-pyridinedicarboxylic acid 2-ethyl ester；2-ethoxycarbonyl-5-[(4-fluorophenyl)methyl]pyridine-3-carboxylic acid
• CAS: 863442-90-4
• 化学式: C₁₆H₁₄FNO₄
• 分子量: 303.29
• InChiKey: ABRNRPOAWFNEMG-UHFFFAOYSA-N

物化性质

• 沸点：
  506.2±50.0 °C(Predicted)
• 密度：
  1.300±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  76.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[(ethoxy)carbonyl]-5-[(4-fluorophenyl)methyl]-3-pyridinecarboxylic acid 在 二苯基膦叠氮化物 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl 3-amino-5-[(4-fluorophenyl)methyl]-2-pyridinecarboxylate
  参考文献：
  名称：

  A Scaleable Synthesis of Methyl 3-Amino-5-(4-fluorobenzyl)-2-pyridinecarboxylate

  摘要：

  A scaleable synthesis of methyl 3-amino-5-(4-fiuorobenzy1)-2-pyridinecarboxylate (1b), starting from 5-bromo-2-methoxypyridine (8) and 4-fluorobenzaidehyde (9), is described. Key steps in the process include lithium-bromine exchange of 8, addition of the resulting lithiate to aldehyde 9, regioselective nitration of pyridone 12, and Pd-catalyzed alkoxycarbonylation of bromopyridine 15b. Overall yield of the five-stage synthesis was 23%; intermediates 10, 12, 13, 15b, and final product 1b center dot HCl were isolated as filterable solids. Compounds 1a,b are important intermediates in the synthesis of 7-benzylnaphthyridinones (e.g., 2) and related HIV-1 integrase inhibitors.

  DOI：

  10.1021/op7001326
• 作为产物：
  描述：

  2-(4-氟苄基)丙烯醛 在 乙酸酐 、 对甲苯磺酸 、 sodium hydroxide 作用下， 生成 2-[(ethoxy)carbonyl]-5-[(4-fluorophenyl)methyl]-3-pyridinecarboxylic acid 、
  参考文献：
  名称：

  A Scaleable Synthesis of Methyl 3-Amino-5-(4-fluorobenzyl)-2-pyridinecarboxylate

  摘要：

  A scaleable synthesis of methyl 3-amino-5-(4-fiuorobenzy1)-2-pyridinecarboxylate (1b), starting from 5-bromo-2-methoxypyridine (8) and 4-fluorobenzaidehyde (9), is described. Key steps in the process include lithium-bromine exchange of 8, addition of the resulting lithiate to aldehyde 9, regioselective nitration of pyridone 12, and Pd-catalyzed alkoxycarbonylation of bromopyridine 15b. Overall yield of the five-stage synthesis was 23%; intermediates 10, 12, 13, 15b, and final product 1b center dot HCl were isolated as filterable solids. Compounds 1a,b are important intermediates in the synthesis of 7-benzylnaphthyridinones (e.g., 2) and related HIV-1 integrase inhibitors.

  DOI：

  10.1021/op7001326

文献信息

• HIV INTEGRASE INHIBITORS
  申请人：ViiV Healthcare Company

  公开号：US20150225399A1

  公开（公告）日：2015-08-13

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明具有作为HIV整合酶抑制剂的化合物，因此在抑制HIV复制、预防及/或治疗HIV感染以及治疗艾滋病及/或艾滋病相关综合症方面具有用途。
• Hiv Integrase Inhibitors
  申请人：Johns Alvin Brian

  公开号：US20070124152A1

  公开（公告）日：2007-05-31

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及一种HIV整合酶抑制剂化合物，因此在抑制HIV复制，预防和/或治疗HIV感染以及治疗艾滋病和/或ARC方面具有用途。
• 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
  申请人：Johns Brian Alvin

  公开号：US08691991B2

  公开（公告）日：2014-04-08

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及能够抑制HIV整合酶的化合物，因此可用于抑制HIV复制，预防和/或治疗HIV感染，以及治疗艾滋病和/或ARC。
• WO2007/19101
  申请人：——

  公开号：——

  公开（公告）日：——
• Synthesis and Antiviral Activity of 7-Benzyl-4-hydroxy-1,5-naphthyridin-2(1<i>H</i>)-one HIV Integrase Inhibitors
  作者：Eric E. Boros、Cynthia E. Edwards、Scott A. Foster、Masahiro Fuji、Tamio Fujiwara、Edward P. Garvey、Pamela L. Golden、Richard J. Hazen、Jerry L. Jeffrey、Brian A. Johns、Takashi Kawasuji、Ryuichi Kiyama、Cecilia S. Koble、Noriyuki Kurose、Wayne H. Miller、Angela L. Mote、Hitoshi Murai、Akihiko Sato、James B. Thompson、Mark C. Woodward、Tomokazu Yoshinaga

  DOI：10.1021/jm801404b

  日期：2009.5.14

  The medicinal chemistry and structure-activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naphthyridinone ring system. Low nanomolar IC50 values were achieved in an HIV-integrase strand transfer assay with both carboxylic ester and carboxamide groups at C-3. More importantly, several carboxamide congeners showed potent antiviral activity in cellular assays. A 7-benzyl substituent was found to be critical for potent enzyme inhibition, and an N-(2-methoxyethyl)-carboxamide moiety at C-3 significantly reduced plasma protein binding effects in vitro. Pharmacokinetic data in rats for one carboxamide analogue demonstrated oral bioavailability and reasonable in vivo clearance.